AnGes, Inc.
https://www.anges.co.jp/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AnGes, Inc.
AnGes To Withdraw, Refile HGF Gene Therapy In Japan
If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.
Healthtech Leaders Discuss Impact (And Risks) Of Generative AI and AI In Health Care
AI and generative AI ruled much of the discussion at HLTH Europe 2024. A panel of health care leaders from Microsoft, Philips, insitro and Johnson & Johnson discussed how these new technologies are already transforming health care and pointed to risks and challenges.
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
AI Assurance Lab Concept Leaves Potential Regulatory Gap
In an interview with Medtech Insight sister publication the Pink Sheet, Troy Tazbaz, director of the US FDA's Digital Health Center of Excellence, says the agency lacks authority to regulate assurance labs, which would be used to help AI developers ensure their models are working correctly before submitting them for approval.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AnGes Co., Ltd.
- AnGes MG
- EmendoBio Inc.
- Emendo Biotherapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice